These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

255 related items for PubMed ID: 18497829

  • 1. Anti-VEGF therapy: comparison of current and future agents.
    Pieramici DJ, Rabena MD.
    Eye (Lond); 2008 Oct; 22(10):1330-6. PubMed ID: 18497829
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [Treatment of neovascular age-related macular degeneration with antiangiogenic drugs].
    Rodrigues EB, Rossi EE, Grumann Junior A, Meyer CH, Ho AC.
    Arq Bras Oftalmol; 2006 Oct; 69(5):756-65. PubMed ID: 17187150
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Antivascular endothelial growth factors in age-related macular degeneration.
    Schmidt-Erfurth U, Pollreisz A, Mitsch C, Bolz M.
    Dev Ophthalmol; 2010 Oct; 46():21-38. PubMed ID: 20703030
    [Abstract] [Full Text] [Related]

  • 8. Quantitative comparison of optical coherence tomography after pegaptanib or bevacizumab in neovascular age-related macular degeneration.
    Joeres S, Kaplowitz K, Brubaker JW, Updike PG, Collins AT, Walsh AC, Romano PW, Sadda SR.
    Ophthalmology; 2008 Feb; 115(2):347-354.e2. PubMed ID: 17628685
    [Abstract] [Full Text] [Related]

  • 9. Management of pediatric choroidal neovascular membranes with intravitreal anti-VEGF agents: a retrospective consecutive case series.
    Kohly RP, Muni RH, Kertes PJ, Lam WC.
    Can J Ophthalmol; 2011 Feb; 46(1):46-50. PubMed ID: 21283157
    [Abstract] [Full Text] [Related]

  • 10. Re: Verteporfin combination regimens in the treatment of neovascular age-related macular degeneration.
    Nelson M.
    Retina; 2010 Feb; 30(2):380; author reply 380-1. PubMed ID: 20142719
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. What we don't know about avastin might hurt us.
    Gillies MC.
    Arch Ophthalmol; 2006 Oct; 124(10):1478-9. PubMed ID: 17030717
    [No Abstract] [Full Text] [Related]

  • 17. A comparative debate on the various anti-vascular endothelial growth factor drugs: pegaptanib sodium (Macugen), ranibizumab (Lucentis) and bevacizumab (Avastin).
    Nagpal M, Nagpal K, Nagpal PN.
    Indian J Ophthalmol; 2007 Oct; 55(6):437-9. PubMed ID: 17951900
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.